PMID- 25160945
OWN - NLM
STAT- MEDLINE
DCOM- 20160309
LR  - 20220408
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 31
IP  - 9
DP  - 2014 Sep
TI  - Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction 
      and improvement in quality of life in clinical practice.
PG  - 961-74
LID - 10.1007/s12325-014-0147-3 [doi]
AB  - INTRODUCTION: In the prospective, open-label multicenter INTENSIFY study, the 
      effectiveness and tolerability of ivabradine as well as its impact on quality of 
      life (QOL) in chronic systolic heart failure (CHF) patients were evaluated over a 
      4-month period. METHODS: In CHF patients with an indication for treatment with 
      ivabradine, resting heart rate (HR), heart failure symptoms [New York Heart 
      Association (NYHA) class, signs of decompensation], left ventricular ejection 
      fraction, brain natriuretic peptide (BNP) values, QOL, and concomitant medication 
      with focus on beta-blocker therapy were documented at baseline, after 4 weeks, 
      and after 4 months. The results were analyzed using descriptive statistical 
      methods. RESULTS: Thousand nine hundred and fifty-six patients with CHF were 
      included. Their mean age was 67 +/- 11.7 years and 56.9% were male. 77.8% were 
      receiving beta-blockers. Other concomitant medications included 
      angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (83%), 
      diuretics (61%), aldosterone antagonists (18%), and cardiac glycosides (8%). At 
      baseline, the mean HR of patients was 85 +/- 11.8 bpm, 51.1% and 37.2% of patients 
      were classified as NYHA II and III, respectively, and 22.7% showed signs of 
      decompensation. BNP concentrations were tracked in a subgroup, and values 
      exceeding 400 pg/mL were noted in 53.9% of patients. The mean value of the 
      European quality of life-5 dimensions (EQ-5D) QOL index was 0.64 +/- 0.28. After 
      4 months of treatment with ivabradine, HR was reduced to 67 +/- 8.9 bpm. 
      Furthermore, the proportion of patients presenting with signs of decompensation 
      decreased to 5.4% and the proportion of patients with BNP levels >400 pg/mL 
      dropped to 26.7%, accompanied by a shift in NYHA classification towards lower 
      grading (24.0% and 60.5% in NYHA I and II, respectively). EQ-5D index improved to 
      0.79 +/- 0.21. CONCLUSION: Over 4 months of treatment, ivabradine effectively 
      reduced HR and symptoms in CHF patients in this study reflecting daily clinical 
      practice. These benefits were accompanied by improved QOL and good general 
      tolerability.
FAU - Zugck, Christian
AU  - Zugck C
AD  - Clinic/Group Practice for Internal Medicine, Steiner Thor, Straubing, Germany, 
      zugck@gmx.net.
FAU - Martinka, Peter
AU  - Martinka P
FAU - Stockl, Georg
AU  - Stockl G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140827
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Benzazepines)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Diuretics)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 3H48L0LPZQ (Ivabradine)
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Benzazepines/*therapeutic use
MH  - Cardiovascular Agents/administration & dosage/*therapeutic use
MH  - Chronic Disease
MH  - Diuretics/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Heart Rate
MH  - Humans
MH  - Ivabradine
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Prospective Studies
MH  - Quality of Life
MH  - Treatment Outcome
PMC - PMC4177104
EDAT- 2014/08/28 06:00
MHDA- 2016/03/10 06:00
PMCR- 2014/08/27
CRDT- 2014/08/28 06:00
PHST- 2014/07/10 00:00 [received]
PHST- 2014/08/28 06:00 [entrez]
PHST- 2014/08/28 06:00 [pubmed]
PHST- 2016/03/10 06:00 [medline]
PHST- 2014/08/27 00:00 [pmc-release]
AID - 147 [pii]
AID - 10.1007/s12325-014-0147-3 [doi]
PST - ppublish
SO  - Adv Ther. 2014 Sep;31(9):961-74. doi: 10.1007/s12325-014-0147-3. Epub 2014 Aug 
      27.